Related Experiment Videos
[Clinical effects of meropenem on infectious diseases in obstetrics and gynecology]
1Shirataka Hospital.
Abstract:
The efficacy and the safety of meropenem (MEPM) were examined in obstetric and gynecological infections and the results shown below were obtained. 1. The subjects were patients with infectious diseases during a non-pregnant period (n = 14), a pregnant period (n = 13) and a puerperal period (n = 11). After intravenous drip infusion of MEPM at 1-2 g/day, the response rate was 38/39 (97.4%) (Excellent: 13/39 (33.3%), Effective: 25/39 (64.1%)). 2. The response rates in a group receiving 1 g/day, a group receiving 2 g/day and a group receiving a combination of both were, respectively, 25/26 (96.2%), 9/9 (100%) and 4/4 (100%). 3. In cases that did not respond to previous treatments, the response rate to MEPM was 20/20 (100%). 4. In clinical efficacy classified by causative organisms, the rate of Excellent was 10/23 (43.5%) and the rate of Effective was 13/23 (56.5%), and the bacterial eradication rate was 21/23 (91.3%). 5. No subjective and objective adverse reactions or abnormalities in clinical laboratory tests due to administration of MEPM were observed.
Insights
Meropenem (MEPM) demonstrated high efficacy and safety in obstetric and gynecological infections, achieving a 97.4% response rate across pregnant and non-pregnant patients. This broad-spectrum antibiotic proved effective even in cases resistant to prior treatments.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Obstetric and gynecological infections pose significant health risks.
- Effective antibiotic therapy is crucial for managing these infections.
- Meropenem (MEPM) is a broad-spectrum carbapenem antibiotic.
Purpose of the Study:
- To evaluate the efficacy and safety of meropenem (MEPM) in treating obstetric and gynecological infections.
- To assess MEPM's effectiveness in different patient populations (non-pregnant, pregnant, puerperal).
- To determine MEPM's response rates in cases refractory to previous treatments.
Main Methods:
- Intravenous drip infusion of meropenem (MEPM) at daily doses of 1-2 g.
- Patient groups included non-pregnant (n=14), pregnant (n=13), and puerperal (n=11) periods.
- Efficacy assessed by response rates, clinical outcomes, and bacterial eradication.
Main Results:
- Overall response rate was 97.4% (38/39 patients).
- Excellent and effective responses were observed in 33.3% and 64.1% of patients, respectively.
- 100% response rate in patients refractory to prior treatments and in pregnant/puerperal groups.
Conclusions:
- Meropenem (MEPM) is highly effective and safe for obstetric and gynecological infections.
- The drug shows excellent efficacy across different patient populations and infection severities.
- No adverse reactions or laboratory abnormalities were reported, highlighting MEPM's favorable safety profile.